Novel photosensitizing properties of porphyrin–chrysin derivatives with antitumor activity in vitro

Abstract

Photodynamic therapy is a promising cancer treatment with the advantages of low toxicity, high efficiency, and noninvasiveness. In this study, 23 novel porphyrin–chrysin derivatives are synthesized using alkyl carbon chains as bridges. We use human gastric cancer cells (MGC-803) and human cervical cancer cells to evaluate the in vitro antitumor activity of all the porphyrin–chrysin derivatives, with 5-fluorouracil (5-Fu) as a positive control. Several of the prepared compounds showed effective photodynamic killing effects, among which 5-hydroxy-2-phenyl-7-(2-(4-(10,15,20-tris(4-hydroxyphenyl)porphyrin-5-yl)phenoxy)ethoxy)-4H-chromen-4-one shows the highest antiproliferation activity on human cervical cancer cells, with a half maximal inhibitory concentration of 26.51 ± 1.15 µM. Flow cytometry analysis showed that human cervical cancer cell apoptosis might be induced by G1 phase arrest.

Keywords

porphyrins chrysins porphyrin-chrysin derivatives synthesis antitumor

Introduction

Photodynamic therapy (PDT) is a new technology that was began to be applied to cancer therapy in the late 1970s. Thereafter, PDT has been accepted by the relevant departments of the United States, the United Kingdom, Germany, Japan, and other countries to enter clinical applications. Until now, this therapy has been used to treat a variety of malignancies successfully.^1–3

The basic elements of PDT can be divided into photosensitizers, specific excitation light, and molecular oxygen. The photosensitizer transfers the absorbed energy to the surrounding oxygen molecules through light irradiation, so that the oxygen molecules become excited singlet oxygen (¹O₂) and other reactive oxygen species (ROS) to achieve the purpose of killing tumor cells.⁴ In fact, the PDT beam is different from the usual clinical laser treatment in that its energy density is low, and its purpose is to activate the photosensitizer without causing tissue damage.

Although a number of photosensitizers have been suggested for PDT,⁵ porphyrins, and their analogs remain the most extensively employed photosensitive compounds.^6,7 Porphyrins have the following advantages for PDT. On one hand, they are satisfactory for singlet oxygen production, and on the other hand, they have the ability to preferentially aggregate in tumor tissues. There are two general theories about the mechanism of specific aggregation of porphyrins in tumor tissues. According to pH theory, most porphyrin molecules enter the cell through passive diffusion. Numerous experiments have shown that porphyrin compounds are more conducive to maintaining the molecular state in a weakly acidic tumor cell environment compared to normal tissues, thereby facilitating their entry into tumor cells in molecular form.^8–10 Based on the theory of low-density lipoproteins (LDLs), the surface of rapidly growing tumor cells contains more LDL receptors that show strong activity. When the porphyrin compound binds to the LDLs, the LDLs transport the drug to bind to receptors on the cell membrane so that the drug can accumulate in the tumor tissue.^11–14 Based on this, a large number of antitumor porphyrin derivatives have been reported.^15–18

Chrysin is a natural flavonoid and has a wide range of pharmacological activities such as anti-inflammatory,^19,20 antioxidant,^21,22 antibacterial,²³ hypoglycemic,²⁴ antitumor,^25–27 and so on. However, there are many shortcomings in the chemical structure of chrysin. Research by scientists in both China and abroad on chrysin has mainly focused on the modification and optimization of its chemical structure. On one hand, chrysin shows poor lipophilic and water-solubility properties, which limits its clinical application. Second, the 5- and 7-hydroxy groups of chrysin are readily inactivated by rapid glycosylation and metabolism in vivo. Therefore, the structural optimization of chrysin in order to improve its bioavailability and activity has been the subject of significant research.^28–30

To this end, we have innovatively combined the antitumor compounds porphyrin and chrysin by appropriate methods. Finally, a series of novel porphyrin–chrysin derivatives have been obtained and the products tested for their performance and in vitro antitumor activity.

Results and discussion

Chemical synthesis

In this study, 23 novel substituted porphyrin–chrysin derivatives have been synthesized. First, we prepared the chrysin and porphyrin derivatives. The chrysin derivatives 1a–1e were synthesized according to the method shown in Scheme 1, typically by alkylation of the chrysin 7-OH with 1, n-dihalogenated alkanes using KI or K₂CO₃, and the resulting compounds were consistent with the literature.^31,32 Porphyrins 2–4 were synthesized according to the classical Adler–Longo method shown in Scheme 2.^33–36 Metalloporphyrins 5 and 6 were obtained after metalizing porphyrins 2 and 3.³⁷ The synthesis of the target compounds 2a–6e followed the general pathway shown in Scheme 3. The porphyrins were dissolved in N,N-Dimethylformamide (DMF); potassium carbonate and potassium iodide were added; and the chrysin derivatives were added after reaction at 80°C for 1 h. The structures of all the target compounds were characterized by ¹H nuclear magnetic resonance (NMR), ultraviolet–visible spectroscopy (UV-Vis), and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (see the Supplemental material).

Performance testing

UV-Vis spectra

As shown in Table 1, the Soret band and the Q band are two characteristic absorption bands of the porphyrin compounds. The Soret band is generally around 418 nm and exhibits strong absorption. The Q band is generally between 500 and 700 nm and exhibits weak absorption. The II band is a characteristic absorption band of flavonoids.³⁸ We found that the Soret band absorption peaks of the derivatives 5 and 6 produced a slight blue shift, and the Q band absorption peaks decreased in intensity from 4 to 1 compared to derivatives 2 and 3. This phenomenon can be explained by the fact that the insertion of nickel reduces the π-electron density of the porphyrin ring and makes the overall structure of the porphyrin molecule more symmetrical, increasing the degeneracy of the molecular orbital (see the Supplemental Material).

Table 1.

UV/Vis absorption spectral data of the porphyrin–chrysin derivatives.^a

Compound	II band (nm)	Soret band (nm)	Q band (nm)
2	—	419	516, 552, 591, 647
2a	270	420	517, 552, 592, 647
2b	270	420	516, 552, 592, 647
2c	270	420	517, 552, 591, 647
2d	270	420	517, 552, 592, 648
2e	270	420	517, 552, 592, 647
5	—	416	529
5a	269	417	529
5b	269	417	529
5c	269	417	529
5d	269	417	529
5e	269	417	529
3	—	421	519, 556, 594, 649
3a	269	420	519, 556, 594, 649
3b	269	420	519, 556, 594, 649
3c	269	421	519, 556, 595, 649
3d	269	421	519, 556, 595, 650
3e	269	421	519, 556, 595, 650
6	—	419	530
6a	269	419	530
6b	269	419	530
6c	269	419	530
6d	269	419	530
6e	269	419	531
4	—	421	519, 556, 594, 650
4a	269	421	519, 556, 594, 650
4b	269	421	519, 556, 594, 650
4c	269	421	519, 556, 594, 650

The structural formulae of the porphyrin–chrysin compounds are shown in Scheme 3.

Fluorescence spectra

The results of fluorescence spectroscopy showed that the maximum fluorescence emission wavelengths of the derivatives 2, 3, and 4 were all around 656 nm, while no fluorescence signal was detected for compounds 5 and 6. Analysis has shown that there is a single electron in the d orbital of the extranuclear electron arrangement of the nickel atom. When the nickel atom is combined with the conjugated porphyrin molecule, this electron is still not paired, causing the entire conjugated structure to be destroyed, so the molecule dose not fluoresce³³ (see the Supplemental material).

Detection of singlet oxygen (¹O₂)

¹O₂ is a powerful ROS, which can effectively induce the apoptosis of tumor cells. 1,3-Diphenylisobenzofuran (DPBF) is a commonly used singlet oxygen–trapping agent, which can be oxidized by singlet oxygen to open the ring and destroy the conjugated structure, resulting in the disappearance of the fluorescence signal. We have used the magnitude and rate of its fluorescence intensity change around 456 nm to evaluate the ability of compounds to produce singlet oxygen.³⁹ As shown in Figure 1, compared with the DPBF control group, the fluorescence intensity of the DPBF solution and the mixed solution of the target compounds porphyrin–chrysin derivatives 2a–6e were decreased to varying degrees, which indicated that the porphyrin–chrysin derivatives had certain singlet oxygen production capacity.

Comparing the presence of Figure 1(b)–(d) with (e) and (f), it can be seen that the free-base porphyrin derivatives 2, 3, and 4 series have a stronger ability to generate singlet oxygen than the metalloporphyrins 5 and 6. Within 10 min of monitoring, the DPBF fluorescence intensity of the porphyrin–chrysin derivatives 2, 3, and 4 was substantially reduced to below 200, while the DPBF fluorescence intensity of Derivatives 5 and 6 was generally between 500 and 800 counts.

Biological activities

In vitro antiproliferative activity assay

The antiproliferative activity in vitro of compounds 2, 3, 4, 5, 6, 2a–2e, 3a–3e, 4a–4c, 5a–5e, and 6a–6e were tested against human tumor cells: MGC-803 (gastric carcinoma cells) and HeLa (cervical carcinoma cells) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to determine the cytotoxicity of the compounds in light and darkness, respectively.⁴⁰ Some compounds exhibited moderate to good antiproliferative activity against the MGC-803 cell and HeLa cell lines.

According to the data in Table 2, the antiproliferative activity of the light group was significantly stronger than that of the dark group. Derivatives 2, 3, and 4 are more cytotoxic than 5 and 6. Among derivatives 2, 3, and 4, derivatives 4 had the best antitumor activity, followed by the derivatives 2, with the compound 3 showing the worst activity. This phenomenon is almost consistent with the ability of the compound to produce singlet oxygen. Compounds 2a, 2c, 2e, 4a, and 4b have high antitumor activity under light conditions. The activity of 4a compound on MGC-803 and HeLa cells was better than that of chrysin and the positive control drug 5-Fu, and its toxicity to HeLa cells was five times that compared to when in the dark.

Table 2.

Anti-proliferative activity against tumor cell lines.

Compound	IC₅₀ (µM)
	MGC-803		HeLa
	Light	Dark	Light	Dark
Chrysin	143.4 ± 4.76		>200
2	148.5 ± 5.08	>200	>200	>200
2a	98.63 ± 3.26	>200	149.8 ± 4.17	>200
2b	>200	>200	>200	N.D
2c	85.75 ± 3.03	>200	131.6 ± 4.24	>200
2d	>200	N.D	166.5 ± 4.11	N.D
2e	81.87 ± 2.87	>200	>200	N.D
5	144.5 ± 3.75	N.D	167.7 ± 3.42	>200
5a	>200	N.D	132.9 ± 4.79	>200
5b	115.2 ± 4.60	>200	N.D	N.D
5c	>200	N.D	N.D	N.D
5d	147.4 ± 3.96	N.D	N.D	N.D
5e	171.6 ± 5.60	N.D	>200	N.D
3	>200	>200	>200	N.D
3a	>200	>200	179.1 ± 4.36	N.D
3b	>200	N.D	>200	N.D
3c	178.7 ± 5.13	>200	>200	N.D
3d	>200	N.D	N.D	N.D
3e	>200	N.D	>200	N.D
6	N.D	N.D	>200	N.D
6a	>200	N.D	>200	N.D
6b	>200	N.D	N.D	N.D
6c	N.D	N.D	N.D	N.D
6d	N.D	N.D	>200	N.D
6e	N.D	N.D	N.D	N.D
4	159.2 ± 3.43	>200	194.7 ± 3.07	>200
4a	70.41 ± 2.15	135.2 ± 2.42	26.51 ± 1.15	142.7 ± 2.45
4b	164.3 ± 5.33	>200	62.79 ± 2.22	170.3 ± 3.25
4c	>200	N.D	>200	N.D
5-Fu	78.37 ± 2.47		72.80 ± 2.27

ND = not detected.

Cell cycle assay

A cell cycle assay was conducted to check the distribution of HeLa cells, treated with compound 4a at different concentrations (0, 20, 40, and 60 µM) over 24 h, in different phases under light conditions. As indicated in Figure 2, with the increase of drug concentration (0, 20, 40, and 60), the percentage of HeLa cells in the G1 phase gradually increased from 69.67% to 72.64%, 75.77%, and 78.85%. In contrast, the percentage of cells in the S and G2 phases gradually decreased. The results showed that compound 4a inhibited HeLa cell proliferation in a concentration-dependent manner and blocked it in the G1 phase.

Apoptosis assay

The flow cytometry assay determined the effect of compound 4a on apoptosis in HeLa cells. The cells were treated with compound 4a at different concentrations (0, 20, 40, and 60 µM) under light conditions for 24 h and were collected, stained with Annexin V-fluorescein isothiocyanate (FITC)/PI, and then examined. In Figure 3, four-quadrant plots, the control group normal cells accounted for 82.6% of the total cell number, and apoptotic cells (Q2 + Q3) were only 15.53%, when the drug concentration was increased to 60 µM, normal cells accounted for only 10.3%, and the number of apoptotic cells increased to 88.58%. Therefore, we can conclude that compound 4a can induce apoptosis in HeLa cells in a concentration-dependent manner.

Conclusion

In summary, a series of novel porphyrin–chrysin derivatives have been synthesized, and these compounds were evaluated for their ¹O₂ and antitumor activities. The results of MTT in vitro antiproliferative experiments showed that compounds 2a, 2c, 2e, 4a, and 4b had higher antiproliferative activity against MGC-803 and HeLa cells under light conditions. Compound 4a had significant inhibitory activity against HeLa cells under light conditions, with the IC₅₀ value (26.51 ± 1.15) being much lower than that of the positive control drug 5-Fu. At the same time, the activity of the free-base porphyrin derivatives is higher than that of the nickel porphyrin derivatives. In addition, the antiproliferative effect of all compounds was significantly enhanced under light conditions compared to dark conditions.

Experimental section

All the starting materials, solvents, and reagents were reagent grade and purchased from commercial sources unless otherwise stated. Chrysin was purchased from Aladdin. ¹H NMR was recorded on a Bruker AVANCE instrument (400 and 500 MHz, Bruker, Germany). MALDI-TOF MS data were recorded using a Bruker Daltonics flex analyzer (Bruker, Germany).

Synthesis methods

Synthesis of chrysin derivatives 1a–1e.^31,32

The appropriate 1, n-dibromoalkane (10 mmol), K₂CO₃ (50 mmol), and KI (50 mmol) were dissolved in acetone (60 mL) and stirred at 60°C for 1 h under reflux. Next, chrysin (508.5 mg, 2 mmol) was slowly added to the reaction system in batches, and the reaction progress was monitored by thin-layer chromatography (TLC) until the reaction was complete. The reaction solution was extracted with dichloromethane and washed twice with water to remove impurities. The organic layer was dried over anhydrous Na₂SO₄, and then the solvent was distilled off under reduced pressure. The residue purified by silica gel column chromatography. The first color band was collected with dichloromethane/n-hexane (3: 1) as eluent, and yellow crystals were obtained by recrystallization from n-hexane.

Synthesis of porphyrin compounds 2, 3, and 4.^33–36

Compounds 2 or 3 were prepared using (6.2 g, 0.05 mol) p-hydroxybenzaldehyde and p-chlorobenzaldehyde (14.0 g, 0.10 mol) or p-methoxybenzaldehyde (13.6 g, 0.10 mol). For compound 4, only of p-hydroxybenzaldehyde (12.4 g, 0.10 mol) was added. Next, propionic acid (200 mL) was added, and the mixture was stirred at 135°C under reflux, and Freshly distilled pyrrole (10.2 g, 0.15 mol) was slowly added dropwise to the reaction solution over 30 min using a constant pressure dropping funnel. After heating and refluxing for 1 h, the reaction was terminated by distilling off two-thirds of the propionic acid under reduced pressure, and an equivalent amount of anhydrous ethanol was added to the reaction solution. The mixture was allowed to stand at 4°C for 24 h, and then filtered under reduced pressure. The residue was washed several times with anhydrous ethanol. The residual solids were purified by silica gel and eluting with dichloromethane to obtain the corresponding porphyrins as purple crystals.

Synthesis of nickel metalloporphyrin compounds 5 and 6.³⁷

Porphyrin 2 (220.2 mg, 0.3 mmol) or 3 (218.4 mg, 0.3 mmol) and a five-fold equivalent amount nickel(II) acetate tetrahydrate were dissolved in DMF (80 mL) and the mixture heated at reflux with stirring. The reaction progress was monitored by TLC. After cooling, the reaction solution was extracted with dichloromethane and washed with water several times to remove excess nickel(II) acetate tetrahydrate. The organic layer was dried over anhydrous Na₂SO₄, the solvent distilled off under reduced pressure, and the obtained crystals recrystallized from anhydrous ethanol to give red-brown crystalline compounds 5 and 6. Compound 5 has not been reported in the literature.

Synthesis of porphyrin–chrysin derivatives 2a–e, 3a–e, 4a–c, 5a–e, and 6a–e

Compound 2 (110.1 mg), 3 (118.1 mg), 5 (118.5 mg), 6 (116.6 mg) (0.15 mmol) was dissolved in DMF (40 mL), and potassium iodide and potassium carbonate were added as acid binding agents, and reacted at 80°C for 30 minutes, and then chrysin derivative 1a–e (0.18 mmol) was added, the temperature remained constant, and the reaction progress was monitored by TLC until complete. The reaction solution was extracted with dichloromethane and washed with water several times to remove impurities such as potassium carbonate and potassium iodide. After drying and concentration, the residue it was purified by silica gel column chromatography (dichloromethane/n-hexane, 3:1) then purified again by gel permeation chromatography and recrystallized from anhydrous ethanol to give red-purple crystalline compounds 2a–e, 3a–e, 5a–e, and 6a–e. Because compounds 4 are susceptible to multiple substitution reactions, they were prepared using a slightly different method. In order to obtain the target compounds and minimize the production of multiple substitution products (difficult to separate), the chrysin derivatives needed to be slowly added to the reaction system in batches. After the reaction was complete, the product was purified by silica gel column chromatography (dichloromethane/ethanol, 12:1). The third color band was collected, then purified again by gel permeation chromatography, and recrystallized from anhydrous ethanol to give red-purple crystals. In fact, small amounts of di- and tri-substituted products were formed but were difficult to separate, so they were not isolated.

5-Hydroxy-2-phenyl-7-(2-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)ethoxy)-4H-chromen-4-one (2a) Yield 15%. ¹H NMR (400 MHz, CDCl₃): δ = 12.80 (s, 1H), 8.90 (d, J = 4.7 Hz, 2H), 8.84 (s, 6H), 8.14 (t, J = 8.2 Hz, 8H), 7.91 (d, J = 7.0 Hz, 2H), 7.75 (d, J = 8.2 Hz, 6H), 7.59 − 7.50 (m, 3H), 7.34 (d, J = 8.3 Hz, 2H), 6.71 (s, 1H), 6.68 (s, 1H), 6.55 (s, 1H), 4.65 (s, 2H), 4.60 (s, 2H), −2.83 (s, 2H); UV/Vis (CHCl₃): λ_max = 270 nm (II band); 420 nm (Soret band); 517, 552, 592, 647 nm (Q bands); Fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₁H₃₉Cl₃N₄O₅⁺ 1012.20 [M + H]⁺, found 1012.12.

5-Hydroxy-2-phenyl-7-(3-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)propoxy)-4H-chromen-4-one (2b) Yield 17%. ¹H NMR (500 MHz, CDCl₃): δ = 12.76 (s, 1H), 8.89 (d, J = 4.2 Hz, 2H), 8.86 − 8.75 (m, 6H), 8.12 (t, J = 8.5 Hz, 8H), 7.91 (d, J = 6.5 Hz, 2H), 7.74 (d, J = 7.1 Hz, 6H), 7.53 (d, J = 7.1 Hz, 3H), 7.31 (d, J = 8.2 Hz, 2H), 6.69 (s, 1H), 6.64 (s, 1H), 6.50 (s, 1H), 4.47 (t, J = 5.7 Hz, 2H), 4.43 (t, J = 5.9 Hz, 2H), 2.55 − 2.45 (m, 2H), −2.83 (s, 2H); UV/Vis (CHCl₃): λ_max = 270 nm (II band); 420 nm (Soret band); 516, 552, 592, and 647 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₂H₄₁Cl₃N₄O₅⁺ 1026.21 [M + H]⁺, found 1026.13.

5-Hydroxy-2-phenyl-7-(4-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)butoxy)-4H-chromen-4-one (2c) Yield 18%. ¹H NMR (500 MHz, CDCl₃): δ = 12.76 (s, 1H), 8.91 (s, 2H), 8.83(s, 6H), 8.13 (t, J = 8.6 Hz, 8H), 7.89 (d, J = 7.2 Hz, 2H), 7.74 (d, J = 7.9 Hz, 6H), 7.50 (t, J = 7.5 Hz, 3H), 7.30 (d, J = 7.9 Hz, 2H), 6.69 (s, 1H), 6.59 (s, 1H), 6.46 (s, 1H), 4.36 (s, 2H), 4.26 (s, 2H), 2.21 (s, 4H), −2.84 (s, 2H); UV/Vis (CHCl₃): λ_max = 270 nm (II band); 420 nm (Soret band); 517, 552, 591, and 647 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₃H₄₃Cl₃N₄O₅⁺ 1040.23 [M + H]⁺, found 1040.15.

5-Hydroxy-2-phenyl-7-((5-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)pentyl)oxy)-4H-chromen-4-one (2d) Yield 25%. ¹H NMR (500 MHz, CDCl₃): δ = 12.75 (s, 1H), 8.91 (d, J = 4.2 Hz, 2H), 8.83 (s, 6H), 8.12 (dd, J = 13.4, 8.3 Hz, 8H), 7.86 (d, J = 6.7 Hz, 2H), 7.74 (d, J = 8.0 Hz, 6H), 7.50 (dt, J = 14.2, 7.5 Hz, 3H), 7.29 (d, J = 8.4 Hz, 2H), 6.65 (s, 1H), 6.56 (d, J = 2.0 Hz, 1H), 6.44 (d, J = 2.0 Hz, 1H), 4.30 (t, J = 6.1 Hz, 2H), 4.17 (t, J = 6.3 Hz, 2H), 2.14 − 1.97 (m, 4H), 1.86 (dd, J = 15.0, 8.0 Hz, 2H), −2.84 (s, 2H); UV/Vis (CHCl₃): λ_max = 270 nm (II band); 420 nm (Soret band); 517, 552, 591, and 648 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₄H₄₅Cl₃N₄O₅⁺ 1054.25 [M + H]⁺, found 1054.16.

5-Hydroxy-2-phenyl-7-((6-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)hexyl)oxy)-4H-chromen-4-one (2e) Yield 26%. ¹H NMR (500 MHz, CDCl₃): δ = 12.76 (s, 1H), 8.94 (d, J = 4.7 Hz, 2H), 8.86 (d, J = 5.7 Hz, 6H), 8.15 (t, J = 7.3 Hz, 8H), 7.88 (d, J = 7.3 Hz, 2H), 7.77 (d, J = 7.8 Hz, 6H), 7.51 (d, J = 7.9 Hz, 3H), 7.31 (d, J = 8.0 Hz, 2H), 6.67 (s, 1H), 6.57 (d, J = 2.2 Hz, 1H), 6.45 (d, J = 2.2 Hz, 1H), 4.30 (t, J = 6.3 Hz, 2H), 4.15 (t, J = 6.4 Hz, 2H), 2.09 − 1.98 (m, 4H), 1.80 − 1.71 (m, 4H), − 2.81 (s, 2H); UV/Vis (CHCl₃): λ_max = 270 nm (II band); 420 nm (Soret band); 517, 552, 592, 647 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₅H₄₇Cl₃N₄O₅⁺ 1068.26 [M + H]⁺, found 1068.19.

5-Hydroxy-2-phenyl-7-(2-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)ethoxy)-4H-chromen-4-one (3a) Yield 17%. ¹H NMR (500 MHz, CDCl₃): δ = 12.79 (s, 1H), 8.97 − 8.69 (m, 8H), 8.12 (d, J = 8.3 Hz, 8H), 7.92 (d, J = 6.5 Hz, 2H), 7.57 − 7.50 (m, 3H), 7.28 (d, J = 8.4 Hz, 8H), 6.71 (s, 1H), 6.65 (d, J = 1.7 Hz, 1H), 6.53 (s, 1H), 4.53 (s, 4H), 4.09 (s, 9H), −2.73 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 420 nm (Soret band); 519, 556, 594, and 649 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₄H₄₈N₄O₈⁺ 1000.35 [M + H]⁺, found 1000.31.

5-Hydroxy-2-phenyl-7-(3-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)propoxy)-4H-chromen-4-one (3b) Yield 17%. ¹H NMR (500 MHz, CDCl₃): δ = 12.76 (s, 1H), 8.86 (d, J = 5.3 Hz, 8H), 8.12 (d, J = 7.2 Hz, 8H), 7.91 (dd, J = 7.5, 1.6 Hz, 2H), 7.52 (d, J = 6.9 Hz, 3H), 7.29 (t, J = 7.2 Hz, 8H), 6.70 (s, 1H), 6.65 (d, J = 2.0 Hz, 1H), 6.51 (d, J = 2.0 Hz, 1H), 4.60 − 4.34 (m, 4H), 4.10 (s, 9H), 2.69 − 2.26 (m, 2H), −2.75 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 420 nm (Soret band); 519, 556, 594, and 649 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₅H₅₀N₄O₈⁺ 1014.36 [M + H]⁺, found 1014.31.

5-Hydroxy-2-phenyl-7-(4-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)butoxy)-4H-chromen-4-one (3c) Yield 23%. ¹H NMR (500 MHz, CDCl₃): δ = 12.77 (s, 1H), 8.87 (s, 8H), 8.12 (d, J = 8.3 Hz, 8H), 7.91 − 7.76 (m, 2H), 7.57 − 7.41 (m, 3H), 7.28 (d, J = 8.4 Hz, 8H), 6.68 (s, 1H), 6.59 (d, J = 2.0 Hz, 1H), 6.46 (d, J = 2.1 Hz, 1H), 4.32 (s, 2H), 4.24 (d, J = 5.2 Hz, 2H), 4.09 (s, 9H), 2.19 (s, 4H), −2.75 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 421 nm (Soret band); 519, 556, 595, and 649 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₆H₅₂N₄O₈⁺ 1028.38 [M + H]⁺, found 1028.34.

5-Hydroxy-2-phenyl-7-((5-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)pentyl)oxy)-4H-chromen-4-one (3d) Yield 28%. ¹H NMR (500 MHz, CDCl₃): δ = 12.74 (s, 1H), 8.86 (s, 8H), 8.12 (d, J = 8.0 Hz, 8H), 7.87 (d, J = 6.6 Hz, 2H), 7.49 (t, J = 7.4 Hz, 3H), 7.29 (d, J = 8.3 Hz, 8H), 6.66 (s, 1H), 6.57 (d, J = 2.0 Hz, 1H), 6.44 (d, J = 1.9 Hz, 1H), 4.30 (t, J = 6.1 Hz, 2H), 4.17 (t, J = 6.3 Hz, 2H), 4.10 (s, 9H), 2.13 − 1.98 (m, 4H), 1.91 − 1.78 (m, 2H), −2.75 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 421 nm (Soret band); 519, 556, 595, and 650 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₇H₅₄N₄O₈⁺ 1042.39 [M + H]⁺, found 1042.35.

5-Hydroxy-2-phenyl-7-((6-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)hexyl)oxy)-4H-chromen-4-one (3e) Yield 28%. ¹H NMR (500 MHz, CDCl₃): δ = 12.75 (s, 1H), 8.88 (s, 8H), 8.12 (t, J = 7.6 Hz, 8H), 7.86 (d, J = 6.7 Hz, 2H), 7.47 (d, J = 7.2 Hz, 3H), 7.28 (d, J = 8.3 Hz, 8H), 6.66 (s, 1H), 6.55 (s, 1H), 6.43 (s, 1H), 4.24 (t, J = 6.2 Hz, 2H), 4.12 (t, J = 6.4 Hz, 2H), 4.08 (s, 9H), 2.04 − 1.99 (m, 2H), 1.98 − 1.90 (m, 2H), 1.75 − 1.64 (m, 4H), −2.74 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 421 nm (Soret band); 519, 556, 595, and 650 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₈H₅₆N₄O₈⁺ 1056.41 [M + H]⁺, found 1056.38.

5-Hydroxy-2-phenyl-7-(2-(4-(10,15,20-tris(4-hydroxyphenyl)porphyrin-5-yl)phenoxy)ethoxy)-4H-chromen-4-one (4a) Yield 16%. ¹H NMR (500 MHz, DMSO-d₆): δ = 12.88 (s, 1H), 9.98 (s, 3H), 8.86 (d, J = 11.9 Hz, 8H), 8.14 (d, J = 6.3 Hz, 4H), 8.00 (d, J = 7.9 Hz, 6H), 7.71 − 7.56 (m, 3H), 7.43 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.1 Hz, 6H), 7.10 (s, 1H), 7.02 (s, 1H), 6.59 (s, 1H), 4.65 (t, J = 6.2 Hz, 2H), 4.56 (t, J = 6.2 Hz, 2H), −2.90 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 421 nm (Soret band); 519, 556, 594, and 650 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₁H₄₂N₄O₈⁺ 958.30 [M + H]⁺, found 958.17.

5-Hydroxy-2-phenyl-7-(4-(4-(10,15,20-tris(4-hydroxyphenyl)porphyrin-5-yl)phenoxy)butoxy)-4H-chromen-4-one (4b) Yield 16%. ¹H NMR (500 MHz, DMSO-d₆): δ = 12.81 (s, 1H), 9.95 (s, 3H), 8.87 (d, J = 5.7 Hz, 6H), 8.83 (s, 2H), 8.08 (dd, J = 14.7, 7.8 Hz, 4H), 8.01 − 7.94 (m, 6H), 7.54 (dt, J = 15.1, 7.2 Hz, 3H), 7.35 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.0 Hz, 6H), 6.99 (d, J = 14.4 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 6.46 (d, J = 2.1 Hz, 1H), 4.32 − 4.20 (m, 4H), 2.04 (s, 4H), −2.88 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 421 nm (Soret band); 519, 556, 594, and 650 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₃H₄₆N₄O₈⁺ 986.33 [M + H]⁺, found 986.21.

5-Hydroxy-2-phenyl-7-((6-(4-(10,15,20-tris(4-hydroxyphenyl)porphyrin-5-yl)phenoxy)hexyl)oxy)-4H-chromen-4-one (4c) Yield 18%. ¹H NMR (500 MHz, DMSO-d₆): δ = 12.81 (s, 1H), 9.98 (s, 3H), 8.87 (s, 6H), 8.83 (s, 2H), 8.09 (d, J = 8.2 Hz, 2H), 8.05 (d, J = 7.5 Hz, 2H), 8.02 − 7.98 (m, 6H), 7.59 − 7.48 (m, 3H), 7.35 (d, J = 8.3 Hz, 2H), 7.20 (d, J = 8.1 Hz, 6H), 7.00 (s, 1H), 6.86 (s, 1H), 6.43 (s, 1H), 4.26 (t, J = 6.1 Hz, 2H), 4.17 (t, J = 6.3 Hz, 2H), 1.96 − 1.89 (m, 2H), 1.88 − 1.80 (m, 2H), 1.61 (dd, J = 15.4, 9.9 Hz, 4H), −2.91 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 421 nm (Soret band); 519, 556, 594, and 650 nm (Q bands); fluorescence (CHCl₃): λ_ex = 417 nm, λ_em = 656 nm; MS (MALDI-TOF): m/z calcd for C₆₅H₅₀N₄O₈⁺ 1014.36 [M + H]⁺, found 1014.23.

Nickel(II)5-Hydroxy-2-phenyl-7-(2-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)ethoxy)-4H-chromen-4-one (5a) Yield 16%. ¹H NMR (500 MHz, CDCl₃): δ = 12.75 (s, 1H), 8.79 (d, J = 4.4 Hz, 2H), 8.72 (d, J = 6.4 Hz, 6H), 7.93 (t, J = 8.5 Hz, 9H), 7.89 (d, J = 7.4 Hz, 2H), 7.67 (d, J = 7.6 Hz, 6H), 7.52 (d, J = 7.7 Hz, 3H), 7.24 (d, J = 7.9 Hz, 2H), 6.68 (s, 1H), 6.60 (s, 1H), 6.48 (s, 1H), 4.43 − 4.36 (m, 4H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 417 nm (Soret band); 529 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₁H₃₇Cl₃N₄NiO₅⁺ 1068.12 [M + H]⁺, found 1068.13.

Nickel(II)5-Hydroxy-2-phenyl-7-(3-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)propoxy)-4H-chromen-4-one (5b) Yield 15%. ¹H NMR (500 MHz, CDCl₃): δ = 12.74 (s, 1H), 8.78 (d, J = 4.4 Hz, 2H), 8.73 − 8.68 (m, 6H), 7.91 (t, J = 8.5 Hz, 8H), 7.88 (d, J = 7.4 Hz, 2H), 7.66 (d, J = 7.6 Hz, 6H), 7.51 (d, J = 7.7 Hz, 3H), 7.23 (d, J = 7.9 Hz, 2H), 6.66 (s, 1H), 6.59 (s, 1H), 6.47 (s, 1H), 4.59 − 4.20 (m, 4H), 2.46 (s, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 417 nm (Soret band); 529 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₂H₃₉Cl₃N₄NiO₅⁺ 1082.13 [M + H]⁺, found 1082.14.

Nickel(II)5-Hydroxy-2-phenyl-7-(4-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)butoxy)-4H-chromen-4-one (5c) Yield 19%. ¹H NMR (500 MHz, CDCl₃): δ = 12.75 (s, 1H), 8.80 (d, J = 4.9 Hz, 2H), 8.73 − 8.69 (m, 6H), 7.91 (t, J = 8.4 Hz, 8H), 7.86 (d, J = 7.0 Hz, 2H), 7.66 (d, J = 8.1 Hz, 6H), 7.52 − 7.45 (m, 3H), 7.21 (d, J = 8.4 Hz, 2H), 6.65 (s, 1H), 6.54 (d, J = 1.9 Hz, 1H), 6.43 (d, J = 1.9 Hz, 1H), 4.29 (d, J = 5.0 Hz, 2H), 4.20 (d, J = 5.2 Hz, 2H), 2.15 (d, J = 2.3 Hz, 4H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 417 nm (Soret band); 529 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₃H₄₁Cl₃N₄NiO₅⁺ 1096.15 [M + H]⁺, found 1096.17.

Nickel(II)5-Hydroxy-2-phenyl-7-((5-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)pentyl)oxy)-4H-chromen-4-one (5d) Yield 18%. ¹H NMR (500 MHz, CDCl₃): δ = 12.73 (s, 1H), 8.80 (d, J = 4.9 Hz, 2H), 8.74 − 8.68 (m, 6H), 7.91 (dd, J = 11.7, 8.4 Hz, 8H), 7.82 (d, J = 7.2 Hz, 2H), 7.65 (d, J = 8.1 Hz, 6H), 7.53 − 7.44 (m, 3H), 7.21 (d, J = 8.4 Hz, 2H), 6.60 (s, 1H), 6.51 (d, J = 2.1 Hz, 1H), 6.40 (d, J = 2.1 Hz, 1H), 4.24 (t, J = 6.2 Hz, 2H), 4.12 (t, J = 6.3 Hz, 2H), 2.06 − 1.96 (m, 4H), 1.85 − 1.77 (m, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 417 nm (Soret band); 529 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₄H₄₃Cl₃N₄NiO₅⁺ 1110.17 [M + H]⁺, found 1110.18.

Nickel(II)5-Hydroxy-2-phenyl-7-((6-(4-(10,15,20-tris(4-chlorophenyl)porphyrin-5-yl)phenoxy)hexyl)oxy)-4H-chromen-4-one (5e) Yield 21%. ¹H NMR (500 MHz, CDCl₃): δ = 12.72 (s, 1H), 8.80 (d, J = 4.7 Hz, 2H), 8.74 − 8.68 (m, 6H), 7.91 (t, J = 9.6 Hz, 8H), 7.80 (d, J = 7.5 Hz, 2H), 7.65 (d, J = 7.9 Hz, 6H), 7.52 − 7.41 (m, 3H), 7.21 (d, J = 8.1 Hz, 2H), 6.58 (s, 1H), 6.48 (s, 1H), 6.39 (s, 1H), 4.21 (t, J = 6.0 Hz, 2H), 4.08 (t, J = 6.2 Hz, 2H), 2.03 − 1.96 (m, 2H), 1.96 − 1.89 (m, 2H), 1.74 − 1.62 (m, 4H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 417 nm (Soret band); 529 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₅H₄₅Cl₃N₄NiO₅⁺ 1124.18 [M + H]⁺, found 1124.19.

Nickel(II)5-Hydroxy-2-phenyl-7-(2-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)ethoxy)-4H-chromen-4-one (6a) Yield 15%. ¹H NMR (500 MHz, CDCl₃): δ = 12.78 (s, 1H), 8.80 − 8.68 (m, 8H), 7.92 (q, J = 8.3 Hz, 10H), 7.58 − 7.47 (m, 3H), 7.21 (d, J = 8.5 Hz, 8H), 6.70 (s, 1H), 6.65 (d, J = 2.0 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.55 (d, J = 10.1 Hz, 4H), 4.04 (s, 9H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 419 nm (Soret band); 530 nm (Q band); MS (MALDI-TOF): m/z calcd for C64H46N4NiO8⁺ 1056.27 [M + H]⁺, found 1056.25.

Nickel(II)5-Hydroxy-2-phenyl-7-(3-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)propoxy)-4H-chromen-4-one (6b) Yield 16%. ¹H NMR (500 MHz, CDCl₃) ¹H NMR (500 MHz, CDCl₃): δ = 12.77 (s, 1H), 8.87 (d, J = 5.3 Hz, 8H), 8.14 (d, J = 7.2 Hz, 8H), 7.94 − 7.90 (m, 2H), 7.53 (d, J = 6.9 Hz, 3H), 7.30 (d, J = 8.0 Hz, 8H), 6.71 (s, 1H), 6.66 (d, J = 2.0 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.46 (dt, J = 13.1, 5.8 Hz, 4H), 4.11 (s, 9H), 2.54 − 2.49 (m, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 419 nm (Soret band); 530 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₅H₄₈N₄NiO₈⁺ 1070.28 [M + H]⁺, found 1070.25.

Nickel(II)5-Hydroxy-2-phenyl-7-(4-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)butoxy)-4H-chromen-4-one (6c) Yield 17%. ¹H NMR (500 MHz, CDCl₃): δ = 12.72 (s, 1H), 8.76 (s, 8H), 7.94 − 7.90 (m, 8H), 7.84 (d, J = 6.6 Hz, 2H), 7.47 (t, J = 7.6 Hz, 3H), 7.21 (d, J = 8.3 Hz, 8H), 6.63 (s, 1H), 6.53 (s, 1H), 6.41 (s, 1H), 4.22 (t, J = 6.1 Hz, 2H), 4.11 (t, J = 6.3 Hz, 2H), 4.04 (s, 9H), 1.99 (d, J = 6.9 Hz, 2H), 1.96 − 1.90 (m, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 419 nm (Soret band); 530 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₆H₅₀N₄NiO₈⁺ 1084.30 [M + H]⁺, found 1084.27.

Nickel(II)5-Hydroxy-2-phenyl-7-((5-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)pentyl)oxy)-4H-chromen-4-one (6d) Yield 20%. ¹H NMR (500 MHz, CDCl₃): δ = 12.73 (s, 1H), 8.76 (s, 8H), 7.92 (dd, J = 5.9, 2.4 Hz, 8H), 7.85 (d, J = 6.6 Hz, 2H), 7.52 − 7.44 (m, 3H), 7.21 (d, J = 8.0 Hz, 8H), 6.63 (s, 1H), 6.54 (d, J = 2.0 Hz, 1H), 6.42 (d, J = 1.9 Hz, 1H), 4.24 (t, J = 6.1 Hz, 2H), 4.14 (t, J = 6.3 Hz, 2H), 4.04 (s, 9H), 2.07 − 1.98 (m, 4H), 1.82 (dd, J = 15.0, 7.9 Hz, 2H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 419 nm (Soret band); 530 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₇H₅₂N₄NiO₈⁺ 1098.31 [M + H]⁺, found 1098.28.

Nickel(II)5-Hydroxy-2-phenyl-7-((6-(4-(10,15,20-tris(4-methoxyphenyl)porphyrin-5-yl)phenoxy)hexyl)oxy)-4H-chromen-4-one (6e) Yield 21%. ¹H NMR (500 MHz, CDCl₃): δ = 12.75 (d, J = 2.0 Hz, 1H), 8.79 (d, J = 2.1 Hz, 8H), 7.94 (dt, J = 10.0, 3.5 Hz, 8H), 7.88 − 7.85 (m, 2H), 7.50 (td, J = 7.4, 6.8, 3.2 Hz, 3H), 7.25 − 7.21 (m, 8H), 6.65 (s, 1H), 6.55 (d, J = 2.3 Hz, 1H), 6.44 (d, J = 2.2 Hz, 1H), 4.25 (t, J = 6.4 Hz, 2H), 4.14 (d, J = 6.4 Hz, 2H), 4.07 (s, 9H), 1.99 (dt, J = 28.0, 6.9 Hz, 4H), 1.72 (d, J = 14.1 Hz, 4H); UV/Vis (CHCl₃): λ_max = 269 nm (II band); 419 nm (Soret band); 531 nm (Q band); MS (MALDI-TOF): m/z calcd for C₆₈H₅₄N₄NiO₈⁺ 1112.33 [M + H]⁺, found 1112.31.

Performance characterization

UV-Vis spectrometry

The test sample was dissolved in chloroform to prepare a working solution having a concentration of 10 μM, and the absorption spectra were scanned between 200 and 800 nm using a UV-Vis spectrophotometer.

Fluorescence spectrometry

The test compounds were accurately weighed using an analytical balance, and all the samples were dissolved in chloroform, and the sample was prepared as a test solution having a concentration of 10 μM. The samples were scanned using an F-7000 FL fluorescence spectrometer with a scanning range of 200–800 nm and an excitation wavelength of 418 nm.

¹O₂ detection

The test compounds were accurately weighed using an analytical balance and all the samples and DPBF were separately dissolved in chloroform. The sample was prepared as a test solution containing a sample (concentration: 10 μM) and DPBF (concentration: 100 μM). The samples were analyzed using an F-7000 FL fluorescence spectrometer. The excitation wavelength was set to 418 nm, the scanning speed was 2400 nm/min, the scanning range was 200–800 nm, and the scanning was performed at intervals of 1 min. The fluorescence changes of DPBF were recorded at 463 nm.

Biological activity detection

In vitro antitumor efficacy

The in vitro antitumor efficacy of the compounds was evaluated using the human tumor cells MGC-803 and HeLa cells in parallel with PDT. Each tested compound was dissolved in dimethyl sulfoxide (DMSO). The cells were plated in 96-well micro-titer plates at a density of 1 × 10⁵ cells per well and incubated in a humidified atmosphere with 5% CO₂ at 37°C for 48 h. One of the experimental groups was removed after the first 4 h. The upper culture medium was carefully removed with a pipette and refilled with the drug-free culture fluid. Light was supplied by a 12 W LED purple lamp located 20 cm from the 96-well plate. Irradiation was continued for 10 min, after which the cells were placed in an incubator to continue the culture incubation. Test compounds of different concentrations (16, 32, 64, 128 μM) were added into triplicate wells and DMSO was used as the control. After 48 h, 20 mL of MTT solution (5 mg mL⁻¹) was added to each well, and incubation was continued for an additional 4 h. Formazan was dissolved in 150 mL of DMSO and added to the wells. The absorbance (optical density, OD) was monitored on a Wellscan MK-2 microplate reader (Lab-Systems) at 490 nm. The IC₅₀ values were determined using the logit method. All experiments were performed three times.

Cell cycle analysis

The HeLa cells were plated in six-well plates (1 × 10⁵ cells per well). After 24 h, the cells were incubated with different concentrations of compound 4a (0, 20, 40, and 60 μM). One of the experimental groups was removed after the first 4 h. The upper culture medium was carefully removed with a pipette and refilled with the drug-free culture fluid. Light was supplied by a 12 W LED purple lamp (50 mW cm⁻², 380–460 nm), located 20 cm from the 96-well plate. After irradiation for 10 min, the cells were placed in an incubator to continue the culture incubation. After 24 h, the cells were washed twice with cold phosphate-buffered saline (PBS) and then re-suspended in cold PBS. Next, the cells were fixed and then stored in 70% cold ethanol for 12 h at 4°C. PI stain (500 mL) was added to the cells in each tube, and the cells were gently vortex mixed and then incubated for 30 min at 37°C in the dark. The cells were analyzed using flow cytometry within 24 h. All experiments were performed three times.

Cell apoptosis assay

The HeLa cells were plated in six-well plates (1 × 10⁵ cells per well). After 24 h, the cells were incubated with different concentrations of compound 4a (0, 20, 40, and 60 μM). One of the experimental groups was removed after the first 4 h. The upper culture medium was carefully removed with a pipette and refilled with the drug-free culture fluid. Light was supplied by a 12 W LED purple lamp located 20 cm from the 96-well plate. After irradiation for 10 min, the cells were placed in an incubator to continue the culture incubation. After 24 h, the cells were washed twice with cold PBS and then re-suspended in binding buffer. Cells were transferred to a 5 mL culture tube, and then 5 mL of FITC Annexin V and 5 mL of PI were added to the cells. Next, the cells were gently vortex mixed and incubated for 15 min at 25°C in the dark. Subsequently, 400 mL of binding buffer was added to each tube. The cells were analyzed using flow cytometry within 1 h. All experiments were performed three times.

Supplemental Material

Supporting_information_2 – Supplemental material for Novel photosensitizing properties of porphyrin–chrysin derivatives with antitumor activity in vitro

Supplemental material, Supporting_information_2 for Novel photosensitizing properties of porphyrin–chrysin derivatives with antitumor activity in vitro by Ding Liu, Qizhi Zhang, Lang Zhang, Wenmei Yu, Huizhi Long, Jun He and Yunmei Liu in Journal of Chemical Research

Footnotes

Acknowledgements

Ding Liu and Qizhi Zhang are contributed equally to this work and should be regarded as co-first authors.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Hunan Provincial Department of Education Key Project (grant no. 18A244), the Hunan Province University Students Research Learning and Innovative Experimental Project (grant no. S201910555017), and the Hunan Natural Science Foundation (grant no. 2018JJ2349).

ORCID iD

Yunmei Liu

Supplemental material

Supplemental material for this article is available online.

References

Robertson

Evans

Abrahamse

J Photochem Photobiol B 2009; 96: 1–8.

You

Liang

Yin

, et al. Theranostics 2018; 8: 1665–1677.

Cheng

Cui

Wang

, et al. ACS Appl Mater Interfaces 2019; 11: 13158.

Dosselli

Tampieri

Ruiz-González

, et al. J Med Chem 2013; 56: 1052–1063.

Park

Cho

Han

, et al. Biomater Sci 2017; 6: 79–90.

Kou

Dou

Yang

Oncotarget 2017; 8: 81591–81603.

Feng

Shi

Xie

, et al. J Med Chem 2018; 61: 7189–7201.

Elfar

Pimstone

Cancer Res 1986; 46: 4390–4394.

Brunner

Arndt

Treittinger

Inorg Chim Acta 2004; 357: 1649–1669.

10.

Kubát

Lang

Anzenbacher

BBA: Gen Subjects 2004; 1670: 40–48.

11.

Polo

Valduga

Jori

, et al. Int J Biochem Cell B 2002; 34: 10–23.

12.

Nakajima

Takemura

Sakata

Cancer Lett 1995; 92: 113–118.

13.

De Smidt

Versluis

van Berkel

. Biochemistry 1993; 32: 2916–2922.

14.

Shibata

Matsumura

Yoshida

, et al. Cancer Lett 2001; 166: 79–87.

15.

Preihs

Arambula

Magda

, et al. Inorg Chem 2013; 52: 12184–12192.

16.

Cheng

Jiang

Kamkaew

, et al. Adv Funct Mater 2017; 27: 2928.

17.

Ogawa

Kiwada

, et al. J Inorg Biochem 2017; 170: 1–7.

18.

Lim

Yang

Phua

, et al. ACS Appl Mater Interfaces 2019; 11: 16391–16401.

19.

Lotito

Frei

J Biol Chem 2006; 281: 37102–37110.

20.

Shin

Kwon

Kim

, et al. Biochem Bioph Res Co 2009; 381: 502–507.

21.

Souza

Antunes

Filho

, et al. Pharmacol Biochem Behav 2015; 134: 22–30.

22.

Freitas

Gaspar

Eur J Pharm Sci 2016; 89: 146–153.

23.

Wang

Qiu

Dong

, et al. J Appl Microbiol 2011; 111: 1551–1558.

24.

Anand

Jaabir

Thomas

, et al. Geriatr Gerontol Int 2012; 12: 741–750.

25.

Zhang

Liu

, et al. PLoS One 2012; 7: e36652.

26.

Dai

Wang

Lin

, et al. Chin J Integr Med 2017; 23: 370–375.

27.

Xuan

Zhang

Wang

, et al. Bioorg Med Chem Lett 2016; 26: 570–574.

28.

Zheng

Meng

, et al. Bioorg Med Chem Lett 2003; 13: 881–884.

29.

Song

Liu

, et al. Med Chem Res 2015; 24: 1789–1798.

30.

Tang

Guo

, et al. Biomed Pharmacother 2016; 82: 693–703.

31.

Shi

, et al. Bioorgan Med Chem 2009; 17: 6264–6269.

32.

Valdez-Calderón

González-Montiel

Martínez-Otero

, et al. J Mol Struct 2016; 1110: 196–207.

33.

Adler

Longo

Shergalis

J Am Chem Soc 1964; 86: 3145–3149.

34.

Huang

Sun

Chem J Chinese U 1983; 4: 381.

35.

Zare-Dorabei

Rahimi

Koohi

, et al. RSC Adv 2015; 5: 93310–93317.

36.

Zhao

Liu

Zheng

, et al. J Nanosci Nanotechno 2016; 16: 9843–9850.

37.

Yang

Liu

Feng

, et al. Chem J Chinese U 1991; 3: 400.

38.

Abdolahzadeh

Boyle

Hoogendijk

, et al. Dalton T 2014; 43: 6322–6332.

39.

Dai

Wang

Gao

, et al. New J Chem 2014; 38: 3569–3578.

40.

Jalde

Chauhan

Lee

, et al. Eur J Med Chem 2018; 147: 66–76.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.98 MB

Novel photosensitizing properties of porphyrin–chrysin derivatives with antitumor activity in vitro

Abstract

Keywords

Introduction

Results and discussion

Chemical synthesis

Performance testing

UV-Vis spectra

Fluorescence spectra

Detection of singlet oxygen (1O2)

Biological activities

In vitro antiproliferative activity assay

Cell cycle assay

Apoptosis assay

Conclusion

Experimental section

Synthesis methods

Synthesis of chrysin derivatives 1a–1e.31,32

Synthesis of porphyrin compounds 2, 3, and 4.33–36

Synthesis of nickel metalloporphyrin compounds 5 and 6. 37

Synthesis of porphyrin–chrysin derivatives 2a–e, 3a–e, 4a–c, 5a–e, and 6a–e

Performance characterization

UV-Vis spectrometry

Fluorescence spectrometry

1O2 detection

Biological activity detection

In vitro antitumor efficacy

Cell cycle analysis

Cell apoptosis assay

Supplemental Material

Supporting_information_2 – Supplemental material for Novel photosensitizing properties of porphyrin–chrysin derivatives with antitumor activity in vitro

Footnotes

Acknowledgements

Declaration of conflicting interests

Funding

ORCID iD

Supplemental material

References

Supplementary Material

Detection of singlet oxygen (¹O₂)

Synthesis of chrysin derivatives 1a–1e.^31,32

Synthesis of porphyrin compounds 2, 3, and 4.^33–36

Synthesis of nickel metalloporphyrin compounds 5 and 6.³⁷

¹O₂ detection